[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

Recruiting now · Early Phase 1

Conditions studied: Stimulator of Interferon Gene, Cancer, Positron Emission Tomography

In brief

Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\[68Ga\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.

Key facts

Study ID

NCT06419361

Run by

First Affiliated Hospital of Chongqing Medical University

People needed

30

Starts

2024-05-30

Expected to finish

2026-12-31

Last updated by the study team

2025-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• At least 18 years of age.
• Signed informed consent.
• Patients with suspected or newly diagnosed or previously malignant disease.

You may not qualify if…

• Patients with non-malignant disease.
• Patients with pregnancy.
• The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
• Known or expected hypersensitivity to [68Ga]Ga-Sa-DABI-4 or any of its components.
• Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.

Where it is running

• The First Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.